Lykos received FDA rejection for MDMA therapy, citing flawed trial design, missing data, and bias. Request for new Phase III trial termed 'deeply disappointing' by CEO.
FDA advisors noted concerns, including a sexual assault allegation during a Phase II trial. Retraction of supporting studies triggered by FDA rejection.
Collection
[
|
...
]